NY-SOUNDTRAP
6.10.2020 14:02:19 CEST | Business Wire | Press release
Soundtrap today launched Soundtrap Capture , a collaborative mobile app for on-the-go music capture and creation. Built with musicians and artists in mind, the new app is an interactive, user-friendly tool that lets creators collaborate in real time, and record high-quality audio whenever and wherever inspiration strikes. Starting today, Soundtrap Capture is available globally to download for free on the iOS App Store .
“This new app is all about capturing creativity whenever, and wherever it strikes. Whether it’s walking down the street, sitting in a cafe or jamming in the studio - the Soundtrap Capture app lets artists collaborate and create right there in the moment.” - Per Emanuelsson, Director of Soundtrap at Spotify.
Soundtrap empowers high-quality collaborative music-making for people around the world, giving creators the opportunity to jam in one place - see who’s recording, vibe to ideas and discuss and react to them in real time. With the Soundtrap Capture app, turning concepts into songs has never been easier.
Developed in conjunction with artists, Soundtrap Capture is an artist-oriented experience focused on the very first step of the music creation process: the concept. It’s this early stage of the creative process - the first strains of melody, the initial ad-libbed verse, the spontaneous guitar riff - that Soundtrap aims to streamline through Soundtrap Capture.
Based on insights from thousands of musicians and their collaborators, Soundtrap set out to simplify the overly complicated music ideation process, which typically involves many musicians toggling between voice notes, messaging apps, digital audio workstations and storage destinations to get their concepts across. Equipped with built-in tools for recording, layering, real-time collaboration and storage, Soundtrap Capture replaces this multi-platform process with one efficient app.
“Empowering artists to create their best work is core to our mission at Spotify,” said Charlie Hellman, Vice President and Head of Marketplace, Spotify. “I'm excited to see Soundtrap Capture help more musicians simplify the creative process and capture sparks of inspiration.”
With an upcoming update, Soundtrap’s Studio tool will soon allow artists to collaborate seamlessly on projects between the Soundtrap Capture app and the Soundtrap Studio app on mobile or desktop. This zero-friction workflow will enable, for example, a musician to start an idea on the go via Soundtrap Capture, and then have a collaborator pick up and build on that idea using Soundtrap Studio from their computer.
Features immediately available on Soundtrap Capture include:
- Multi-track Layering: layer track recordings, instruments and vocals over one another to create different takes.
- Collaborate with Creators: invite multiple collaborators to join a project, present ideas, record and layer tracks to create songs together in real time.
- Live Storage: immediately sync and back up all projects to the Soundtrap system, and easily access them so that you never lose an idea again.
And coming later this year:
- Seamless Integration: transfer seamlessly between the Soundtrap Capture app and the Soundtrap Studio, between desktop and mobile, all without missing a beat.
ABOUT SOUNDTRAP
A part of Spotify, Soundtrap is the first cloud-based recording platform for music and podcasts that works on all operating systems, enabling people to collaborate and record together wherever they are. With an easy-to-use creation platform, Soundtrap empowers creators to build original content using a combination of software instruments, real instruments and audio recording. For more information, please visit https://www.soundtrap.com .
MEDIA ASSETS
Available for download HERE .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom